Effects of Proton Pump Inhibitors on Kidney Transplant Recipients

Completed

• Conditions: Transplant Dysfunction; Magnesium Disorder

• Registration Number: NCT03123796
• Lead Sponsor: Istanbul University

Brief Summary

Use of proton pump inhibitors (PPIs) is quite common among renal transplant recipients and reduced kidney functions and hypomagnesemia with the use of PPIs have been reported. In this study, investigation of the effects of PPI use on the outcome of kidney transplant recipients is aimed.

Detailed Description

Use of proton pump inhibitors (PPIs) is frequent among renal transplant recipients due to the common use of glucocorticoids in immunosuppresive regimens after transplantation. Reduced kidney functions and hypomagnesemia with the use of PPIs have been reported in various patient populations. However, few studies examined the effects of PPIs on kidney transplant recipients. Therefore, the aim of this study is to investigate the effects of PPI and/or histamine H2 receptor antagonist use on serum magnesium levels, allograft functions and survival in kidney transplant recipients.

Study Timeline

• Study Start: 2016-12
• Study First Submitted: 2017-04-19
• Study First Submitted QC: 2017-04-19
• Study First Posted: 2017-04-21
• Primary Completion: 2017-09
• Study Completion: 2017-11
• Status Verified: 2017-12
• Last Update Submitted: 2017-12-25
• Last Update Posted: 2017-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists (Only PPI).
• Kidney transplant recipients who used histamine H2 receptor antagonists and did not use proton pump inhibitors (Only H2RA).
• Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists (PPI and H2RA).
• Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists (No Acid Suppressive Treatment).

Exclusion Criteria

• Patients who are unwilling or unable to consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Graft survival	5-10 years

Secondary Outcome Measures

Name	Time	Method
Graft rejection	5-10 years

Trial Locations

Locations (1)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine; 🇹🇷 İstanbul, Turkey